Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Mar 13, 2024

Cody Shandraw, President and Co-Founder of Healing Realty Trust, aims to provide robust mental and behavioral health treatment facilities. The lack of infrastructure has been a significant hurdle for expanding the commercialization of drugs that require longer in-office visits and space to accommodate the needs of patients undergoing treatments. The emerging field of psychedelics for treating neurological conditions like PTSD requires clinicians to understand the physical requirements for treatment facilities to provide privacy and comfort during the extended time necessary for many of these treatments. 

Cody explains, "In 2020, it was a really interesting stat that I was made aware of at one of the conferences down here in Miami. It was around a drug called Spravato, which is an intranasal ketamine drug. And they were very excited about the launch. It was in development for quite some time, and unfortunately, it didn't commercialize, I think, to their expectations. I asked one of the drug reps down here in Florida why he thought that was, and he said it was a really simple answer: the lack of infrastructure."

"It's a unique drug, and we've only seen this a couple of times. Maybe proton therapy or dialysis centers where when a new therapy is approved, you need that infrastructure to go along with that therapy. And that is what Spravato was. You actually had to be in a clinic for two hours after administration for Spravato. So it was a very unique thing. And a lot of the legacy behavioral mental health providers that would be the target market for that drug, they didn't want to disrupt normal patient inflows into their clinic. So it took a couple of years. When that drug was launched, there were less than a hundred clinics in the United States offering that. Today, there are 2,700 of those clinics, and now Spravato is a blockbuster drug."

#HealingRealtyTrust #CommercialRealEstate #BehavioralHealth #EmergingTherapies #PsychedelicAssistedTherapy #PatientAccess #HealthcareInfrastructure #ImprovingBehavioralHealth

HealingRT.com

Download the transcript here

Healing Realty Trust